Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Shadia Jalal"'
Autor:
Valentina Boni, Mary J. Fidler, Hendrik-Tobias Arkenau, Alexander Spira, Funda Meric-Bernstam, Nataliya Uboha, Rachel E. Sanborn, Randy F. Sweis, Patricia LoRusso, Misako Nagasaka, Javier Garcia-Corbacho, Shadia Jalal, James J. Harding, Stella K. Kim, Iris H.C. Miedema, Danielle J. Vugts, Marc C. Huisman, Gerben J.C. Zwezerijnen, Guus A.M.S. van Dongen, C. Willemien Menke van der Houven van Oordt, Song Wang, Tam Dang, Ivan A. Zein, Olga Vasiljeva, Susan K. Lyman, Virginia Paton, Alison Hannah, Joyce F. Liu
Publikováno v:
Clinical Cancer Research, 28(10), 2020-2029. American Association for Cancer Research Inc.
Purpose: Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAb conjugated to DM4, with a protease-cleavable linker and a peptide mask that limits target engagement in normal tissue an
Autor:
Kathryn F. Mileham, Caroline Schenkel, Suanna S. Bruinooge, Janet Freeman‐Daily, Upal Basu Roy, Amy Moore, Robert A. Smith, Elizabeth Garrett‐Mayer, Lauren Rosenthal, Edward B. Garon, Bruce E. Johnson, Raymond U. Osarogiagbon, Shadia Jalal, Shamsuddin Virani, Mary Weber Redman, Gerard A. Silvestri
Publikováno v:
Cancer Medicine, Vol 11, Iss 2, Pp 530-538 (2022)
Cancer Medicine
Cancer Medicine
Background An ASCO taskforce comprised of representatives of oncology clinicians, the American Cancer Society National Lung Cancer Roundtable (NLCRT), LUNGevity, the GO2 Foundation for Lung Cancer, and the ROS1ders sought to: characterize U.S. oncolo
Publikováno v:
Clinical advances in hematologyoncology : HO. 11(9)